Abstracts tagged "Biologic drugs"

Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab
Daniela Opris¹, Diana Mazilu², Violeta Bojinca³, Andreea Borangiu², Andra Balanescu⁴, Denisa Predeteanu⁵ and Ruxandra Ionescu⁴, ¹53 Tineretului Blvd, Bl. 65, s, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ²Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Intr. Carol Knappe Nr. 9A, Sec, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁴Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁵Bld.Mircea Voda Nr 36., Bl M6,, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania
Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…
Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 1913 • 2013 ACR/ARHP Annual Meeting
Expectations RA Patients Have For Their Treatment – A Comparison Of Clinical Results For Biologic and Disease-Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts
Tsukasa Matsubara^1,2, Hiroaki Matsuno², Tomomaro Izumihara², Yuichi Takahashi², Akira Sagawa², Motohiro Oribe², Eisuke Shono², Kensuke Kume², Masanori Adachi², Yuichi Nishioka², Nobumasa Miyake², Keisuke Hashimoto², Toshikaki Miyamoto², Shigeto Kiyokawa², Tomohiko Yoshida², Syoichi Kondo², Yoshiki Shiohira², Takanori Azuma², Yukio Sato², Masaaki Yoshida², Kenji Mannami², Akihiko Nakamura², Yasuhiko Hirabarashi², Keiko Funahashi³ and James E. Middleton⁴, ¹Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Japan, ²Japanese Clinician's Biologic Research Group, Kobe, Japan, ³Department of Clinical Research, Matsubara Mayflower Hospital, Kato, Japan, ⁴Research Institute of Joint Diseases, Kobe, Japan
Background/Purpose: Treat to Target (T2T) primary principal - “The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist”. Japan…
Abstract Number: 1736 • 2013 ACR/ARHP Annual Meeting
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Jan Brzezicki⁸, Eun Young Lee⁹, Francisco G. Medina-Rodriguez¹⁰, Pavel Shesternya¹¹, Sebastiao Radominski¹², Marina Stanislav¹³, Volodymyr Kovalenko¹⁴, Dong Hyuk Sheen¹⁵, Mie Jin Lim¹⁶, Jung-Yoon Choe¹⁷, Sung Young Lee¹⁸, Seung-Cheol Shim¹⁹ and Chang-Hee Suh²⁰, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Wojewodzki Szpital Zespolony Oddzial Reumatologiczny, Elblag, Poland, ⁹Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁰Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹¹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹²CETI Centro de Estudos em Terapias Inovadoras Ltda, Curitiba, Brazil, ¹³Central Russian National Institute of Rheumatology, Russian Academy of Medical Science, Moscow, Russia, ¹⁴Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁵Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹⁶Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁷Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ¹⁸Clinical Planning and Medical Affairs Department, CELLTRION, Inc., Incheon, South Korea, ¹⁹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²⁰Department of Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose: CT-P10 was developed as a biosimilar candidate to innovator rituximab (RTX), an anti-CD20 monoclonal antibody. This trial is a phase I study to demonstrate…
Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting
Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?
Elizabeth V. Arkema¹, Jerker Jonsson², Eva Baecklund³, Maud Rutting⁴, Judith Bruchfeld⁵, Nils Feltelius⁴ and Johan Askling^1,6, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Swedish Institute for Communicable Disease Control, Solna, Sweden, ³Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, ⁴Swedish Medical Products Agency, Uppsala, Sweden, ⁵Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…
Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
I.M. Markusse¹, G. Akdemir¹, M. van den Broek¹, L. Dirven¹, R.J. Goekoop², K.H. Han³, M. van Oosterhout⁴, P.J.S.M. Kerstens⁵, W.F. Lems⁶, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…
Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Boulos Haraoui¹, Algis V Jovaisas², William G. Bensen³, Rafat Y. Faraawi⁴, John T. Kelsall⁵, Sanjay Dixit⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, Francois Nantel⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1469 • 2013 ACR/ARHP Annual Meeting
Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1^st Anti-TNF: Results of the Multicenter Randomized Controlled “ROC” Trial
Jacques-Eric Gottenberg¹, Olivier Brocq², Aleth Perdriger³, Slim Lassoued⁴, Jean-Marie Berthelot⁵, Daniel Wendling⁶, Liana E. euller-Ziegler⁷, Martin Soubrier⁸, Christophe Richez⁹, Bruno Fautrel¹⁰, Arnaud L. Constantin¹¹, Xavier Mariette¹², Jacques Morel¹³, Melanie Gilson¹⁴, Grégoire Cormier¹⁵, Jean Hugues Salmon¹⁶, Stephanie Rist¹⁷, Frédéric Liote¹⁸, Hubert Marotte¹⁹, Christine Bonnet²⁰, Christian Marcelli²¹, Jeremie Sellam²², Olivier Meyer²³, Elisabeth Solau-Gervais²⁴, Sandrine Guis²⁵, Jean-Marc Ziza²⁶, Charles Zarnitsky²⁷, Isabelle Valckenaere²⁸, Olivier Vittecoq²⁹, Alain Saraux³⁰, Yves-Marie Pers³¹, Martine Gayraud³², Gilles Bolla³³, Pascal Claudepierre³⁴, Marc Ardizzone³⁵, Emmanuelle Dernis³⁶, Maxime A. Breban³⁷, Olivier Fain³⁸, Jean-Charles Balblanc³⁹, Ouafaa Aberkane¹, Marion Vazel¹, Christelle Back¹, Elodie Perrodeau⁴⁰, Philippe Ravaud⁴¹ and Jean Sibilia⁴², ¹Strasbourg University Hospital, Strasbourg, France, ²Hospital of Princesse Grâce de Monaco, Monaco, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Cahors Hospital, Cahors, France, ⁵Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁶Rheumatology, University Hospital, Besancon, France, ⁷Service de Rhumatologie, L Archet Hospital (University), Nice CEDEX 3, France, ⁸Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ⁹Pellegrin Hospital, Bordeaux, France, ¹⁰Rheumatology, UPMC - Paris 6 University, Paris, France, ¹¹Rheumatology, Purpan University Hospital, Toulouse, France, ¹²Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹³Montpellier University Hospital, Montpellier, France, ¹⁴CH Grenoble Hopital Sud, Grenoble, France, ¹⁵CHD Les Oudairies, LA ROCHE SUR YON, France, ¹⁶Reims Hospital, Reims, France, ¹⁷Rheumatology, Orleans Hospital, Orleans, France, ¹⁸Hôpital Lariboisière, Paris, France, ¹⁹INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ²⁰department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ²¹Rheumatology Department, Caen University Hospital, CAEN, France, ²²Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, ²³Rheumatology, Hopital Bichat, Paris, France, ²⁴Poitiers University Hospital, Poitiers, France, ²⁵Rheumatology1, CRMBM UMR CNRS 7339, Aix Marseille Univ; AP-HM, Marseille, France, ²⁶Rheumatology, Croix Saint Simon Hospital, Paris, France, ²⁷Rheumatology, CH du Havre, Le Havre, France, ²⁸Nancy University Hospital, Nancy, France, ²⁹RouenUniversity Hospital, Rouen, France, ³⁰Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ³¹Department of Immuno-Rhumatology, CHU Lapeyronie, Montpellier, France, ³²Institut Montsouris, Paris, France, ³³Cannes Hospital, Cannes, France, ³⁴Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, ³⁵Mulhouse Hospital, Mulhouse, France, ³⁶Le Mans Hospital, Le Mans, France, ³⁷Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ³⁸Internal Medicine, Jean Verdier Hospital, Bondy, France, ³⁹Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ⁴⁰Epidemiology, Hotel Dieu, Paris, France, ⁴¹Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴²Rheumatology, CHU Hautepierre, Strasbourg, France
Background/Purpose: TNF inhibitors often represent the 1st biologic prescribed to patients with rheumatoid arthritis (RA). Approximately one third of patients fail to respond. However, therapeutic…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Adrian Levitsky¹, Kristina Forslind^2,3 and Ronald F. van Vollenhoven⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…
Abstract Number: 997 • 2013 ACR/ARHP Annual Meeting
Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Nick Bansback¹, Eric Fu², Daphne Guh², Huiying Sun², Wei Zhang², Diane Lacaille^3,4 and Aslam H. Anis¹, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Expenditure on biologic therapies for rheumatoid arthritis (RA) accounts for the highest pharmaceutical spending in many western healthcare systems. Given their clinical benefit with…
Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Jinoos Yazdany¹, R. Adams Dudley², Randi Chen³ and Chien-Wen Tseng⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, ³Pacific Health Research and Education Institute, Honolulu, HI, ⁴Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…
Abstract Number: 2808 • 2013 ACR/ARHP Annual Meeting
Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Hélène Bauer¹, Cécile Luxembourger², Sophie Fournier³, Alain G. Cantagrel⁴, Jean Marie Peron³, Anne Marie Roque Afonso⁵, Pascal Claudepierre⁶, S. Fabre⁷, Christophe Hudry⁸, Guillaume Lefevre⁹, Antoine Martin¹⁰, Laurent Messer¹¹, Béatrice Pallot Prades¹², Christian Roux¹³, Christelle Sordet¹⁴, Claire Veissier¹⁵, Daniel Wendling¹⁶, Jacques-Eric Gottenberg¹⁷ and Jean Sibilia¹⁸, ¹rhumatologie, CHU de Hautepierre, Strasbourg, France, ²rhumatologie, CHU de Toulouse, Toulouse, France, ³Hépato-gastro-entérologie, CHU de Toulouse, Toulouse, France, ⁴Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵INSERM U785, CNR hépatites A et E, virologie hôpital Paul Brousse, Villejuif, France, ⁶Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, ⁷Unité clinique d'immuno-rhumatologie, CHU MONTPELLIER, Montpellier, France, ⁸Rheumatology, Hopital Cochin, Paris, France, ⁹Lille University Hospital, Internal Medicine Department, Lille, France, ¹⁰Rhumatologie, Centre Hospitalier De St Brieuc, St Brieuc, France, ¹¹Rhumatologie, Hopitaux Civils de Colmar, Colmar, France, ¹²Rhumatologie, CHU St Etienne, St Etienne, France, ¹³Rheuamtology, CHU L' Archet University Nice, Nice, France, ¹⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁵rhumatologie, CHU de Bordeaux, Bordeaux, France, ¹⁶Rheumatology, University Hospital, Besancon, France, ¹⁷Strasbourg University Hospital, Strasbourg, France, ¹⁸Rheumatology, CHU Hautepierre, Strasbourg, France
Background/Purpose: In inflammatory rheumatic diseases, the prevalence, clinical presentation and outcome of hepatitis E, an ubiquitous viral infection, remain unknown. We therefore addressed these issues…
Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Philip J. Mease¹, Emily Edson-Heredia², Katherine C. Saunders³, Catherine L. Shuler², Baojin Zhu², Monica Chaudhari⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Eli Lilly and Company, Indianapolis, IN, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].